WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 | 3 | 4 | 5 |   ...   | 172 |

«11 1 Jordan National Drug Formulary 2 Jordan National Drug Formulary Disclaimer Jordan National Drug Formulary (JNDF) is for information purposes and ...»

-- [ Page 1 ] --

JORDAN NATIONAL DRUG FORMULARY

Version 2

2011

1

Jordan National Drug Formulary

2

Jordan National Drug Formulary

Disclaimer

Jordan National Drug Formulary (JNDF) is for information purposes and is designed as a general

drug and therapeutic information reference for health care professionals and students in Jordan

Information listed in the JNDF conforms with the Jordanian rational drug policy

The information in the JNDF should be used in conjunction with the most recent information included with each drug or therapeutic agent by the manufacturer.

The authors do not warrant the accuracy of the information contained in the JNDF and do not take responsibility for any loss, damage or injury caused by using the information in the JNDF While every effort has been made to ensure that the JNDF information is correct and in accordance with current recommendations and clinical practice, the dynamic nature of drug information requires that users exercises in all cases independent professional judgment and understand the individual clinical situation when referring, prescribing or providing information from JNDF.

Listing of proprietary names for any drugs for which patent or trademarks exist is not intended as a grant or authority to exercise any rights over the patent or trademarks by Jordan Food and Drug Administration (JFDA).

The following technical references were used in preparation of this JNDF Jordan National Drug Formulary, 2006 Australian Medicine Handbook, 2010 British National Formulary 59 Martindale, 36 edition WHO Model Formulary, 2008 Physicians Desktop Reference (PDR), 2010 JNDF Editors Pharmacist Adi Nuseirat Head of Rational Drug Use department / JFDA Pharmacist Lubna Qusous Rational Drug Use department / JFDA JNDF Designer Mr. Mohammad Ghanem IT unit / JFDA 3 Jordan National Drug Formulary 4 Jordan National Drug Formulary Preface A strong pharmaceutical support system is recognized as an essential component of successful primary health care. In seeking better health outcomes, a list of rational medicines will not only improve the availability of medicines, but will also promote the safe, effective, and rational use of such medicines.

In line with the goals of our National Drug Policy, this document seeks to further improve affordability, accessibility, sustainability and to provide objective information to our health care professionals.

This second edition of the Jordan National Drug Formulary is made available with significant involvement from health care experts, opinion leaders, and from those utilizing the first edition.

I give my deep thanks and appreciation to those who participated in the technical committees and to Rational Drug Use department staff within the JFDA who participated in updating relevant information, revising the text, and making final editing; their contribution has been crucial in publishing this essential document.

Minister of Health Dr. Nayef Al-Fayez

–  –  –

The Jordan National Drug Formulary has been published with collaboration of Ministry of health, Royal medical services, Jordan university hospital, King Abdullah university hospital, Joint procurement department, and Jordan food and drug administration.

JNDF for rational drug list is published, simply to provide easy reference for health care providers in Jordan and provide information about therapeutic classification, action, indication, administration, adverse effects, contraindications, available trade names, dosage forms, patient counseling and drug monitoring.

JNDF is intended for rapid reference and cannot always contain all information necessary for prescribing and dispensing.

I would like to express my deep thanks and appreciation to those who participated and help in editing and publishing this important document.

JFDA Director General Dr. “Mohammad Said” Al-Rawabdeh

–  –  –

Acronyms ________________________________________________________________ 34 CHAPTER 01 GASTRO-INTESTINAL SYSTEM ___________________________ 35

01.01 DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE _______ 35 Dyspepsia_________________________________________________________________________ 35 Gastro-oesophageal reflux disease ________________________________________________ 35 NSAID-related ulcers ______________________________________________________________ 38 01.01.01 Anti-acids ___________________________________________________________________ 38 ALUMINIUM HYDROXIDE __________________________________________________________ 39 MAGNESIUM ANTACIDS ___________________________________________________________ 39 SIMETICONE (activated DIMETICONE) ____________________________________________ 39

01.02 ANTISPASMODICS AND OTHER DRUGS ALTERING GUT MOTILITY _ 40 Nausea and vomiting ______________________________________________________________ 40 01.02.01 Antispasmodics______________________________________________________________ 41 CHLORDIAZEPOXIDE+CLNIDINIUM BROMIDE _____________________________________ 41 CHLORDIAZEPOXIDe ______________________________________________________________ 41 CLIDINIUM BROMIDE _____________________________________________________________ 42 OTILONIUM BROMIDE _____________________________________________________________ 42 01.02.02 Antimuscarinics _____________________________________________________________ 43 HYOSCYAMINE (HYOSCINE BUTYL BROMIDE) _____________________________________ 43 01.02.03 Dopamine Antagonists ( Antiemetics) _______________________________________ 44 DOMPERIDONE ___________________________________________________________________ 44 METOCLOPRAMIDE ________________________________________________________________ 44 01.02.04 5HT3 Antagonists __________________________________________________________ 45 ONDANSETRON ___________________________________________________________________ 45 TROPISETRON ____________________________________________________________________ 46 01.02.05 Other Antispasmodics ______________________________________________________ 47 MEBEVERINE ______________________________________________________________________ 47





01.03 ULCER HEALING DRUGS_______________________________________________ 47 01.03.01 H2 Receptor Antagonists ____________________________________________________ 47 FAMOTIDINE ______________________________________________________________________ 47 RANITIDINE ______________________________________________________________________ 48 01.03.02 Chelates and Complexes (Cytoprotective Agents) ____________________________ 48 BISMUTH SUBCITRATE ____________________________________________________________ 48 01.03.03 Proton Pump Inhibitors ______________________________________________________ 49 ESOMEPRAZOLE __________________________________________________________________ 49 LANSOPRAZOLE ___________________________________________________________________ 50 OMEPRAZOLE _____________________________________________________________________ 51 PANTOPRAZOLE ___________________________________________________________________ 51 01.03.04 Other Ulcer Healing Drugs (Gastrointestinal Haemorrhage) __________________ 52 SOMATOSTATIN __________________________________________________________________ 52 TERLIPRESSIN ____________________________________________________________________ 53

01.04 ACUTE DIARRHOEA____________________________________________________ 53 01.04.01 Antimotility Drugs ___________________________________________________________ 53 9 Jordan National Drug Formulary LOPERAMIDE ______________________________________________________________________ 53

01.05 CHRONIC BOWEL DISORDERS ________________________________________ 54 Inflammatory bowel disease_______________________________________________________ 54 01.05.01 Aminosalicylates ____________________________________________________________ 56 MESALAZINE ______________________________________________________________________ 56 SULFASALAZINE __________________________________________________________________ 57 01.05.02 Corticosteroids _____________________________________________________________ 57 BUDESONIDE _____________________________________________________________________ 57

01.06 LAXATIVE DRUGS _____________________________________________________ 58 01.06.01 Bulk Forming Laxatives _____________________________________________________ 58 BULKING AGENTS _________________________________________________________________ 58 01.06.02 Stimulant laxatives _________________________________________________________ 59 BISACODYL _______________________________________________________________________ 59 CASTOR OIL ______________________________________________________________________ 59 GLYCEROL ________________________________________________________________________ 60 SENNA ____________________________________________________________________________ 60 01.06.04 Osmotic laxatives ___________________________________________________________ 60 LACTULOSE _______________________________________________________________________ 60 PHOSPHATE ENEMA _______________________________________________________________ 61 01.06.05 Bowel cleansing solution ____________________________________________________ 62 MACROGOL _______________________________________________________________________ 62

01.07 LOCAL PREPARATIONS FOR ANAL AND RECTAL DISORDERS _______ 62 Perianal disorders _________________________________________________________________ 62 01.07.01 Soothing Haemorrhoidal Preparations _______________________________________ 63 ANORECTAL PRODUCTS ___________________________________________________________ 63 01.07.02 Compound Haemorrhoidal Preparations with Corticosteroids ________________ 63 01.07.03 Rectal Sclerosants __________________________________________________________ 64 ETHANOLAMINE OLEATE __________________________________________________________ 64

01.09 DRUGS AFFECTING INTESTINAL SECRETIONS ______________________ 64 01.09.01 Drugs Affecting Biliary Composition and Flow ________________________________ 64 URSODEOXYCHOLIC ACID ________________________________________________________ 64 01.09.02 Pancreatic Enzymes _________________________________________________________ 65 01.09.03 Treatment of Hepatic Encephalopathy _______________________________________ 65 ORNITHINE ASPARTATE ___________________________________________________________ 65 Table 01.01 Recommended H. Pylori Eradication Regimens _______________ 66 Table 01.02 Comparison of Laxative Classes _______________________________ 66 CHAPTER 02 CARDIOVASCULAR SYSTEM _____________________________ 67

02.01 POSITIVE INOTROPIC DRUGS ________________________________________ 67 02.01.01 Cardiac Glycosides __________________________________________________________ 67 DIGOXIN __________________________________________________________________________ 67

02.02 DIURETICS _____________________________________________________________ 69 02.02.01 Thiazides and Related Diuretics ______________________________________________ 69 HYDROCHLOROTHIAZIDE _________________________________________________________ 70 INDAPAMIDE ______________________________________________________________________ 70 02.02.02 Loop Diuretics _______________________________________________________________ 72 BUMETANIDE _____________________________________________________________________ 72 FUROSEMIDE _____________________________________________________________________ 73 02.02.03 Potassium Sparing Diuretics _________________________________________________ 74 10 Jordan National Drug Formulary SPIRONOLACTONE ________________________________________________________________ 74 02.02.04 Potassium Sparing diuretics with other diuretics _____________________________ 75 AMLORIDE + HYDROCHLOROTHIAZIDE ___________________________________________ 75 AMILORIDE _______________________________________________________________________ 75 TRIAMTERENE + HYDROCHLOROTHIAZIDE ________________________________________ 76 TRIAMTERENE ____________________________________________________________________ 76

02.03 ANTI-ARRHYTHMIC DRUGS ___________________________________________ 76 02.03.01 Drugs for Arrhythmia ________________________________________________________ 76 Arrhythmias ______________________________________________________________________ 77 Bradyarrhythmias _________________________________________________________________ 77 Tachyarrhythmias _________________________________________________________________ 78 ADENOSINE _______________________________________________________________________ 80 AMIODARONE _____________________________________________________________________ 81 FLECAINIDE_______________________________________________________________________ 82 LIDOCAINE _______________________________________________________________________ 83 PROPAFENONE ____________________________________________________________________ 84

02.04 BETA-ADRENOCEPTOR BLOCKING DRUGS ___________________________ 84 02.04.01 Cardioselective ______________________________________________________________ 87 ATENOLOL ________________________________________________________________________ 87 BETAXOLOL _______________________________________________________________________ 88 BISOPROLOL ______________________________________________________________________ 89 METOPROLOL _____________________________________________________________________ 90 NEBIVOLOL _______________________________________________________________________ 91 02.04.02 Non Cardioselective _________________________________________________________ 91 CARVEDILOL ______________________________________________________________________ 91 LABETALOL _______________________________________________________________________ 92 NADOLOL _________________________________________________________________________ 92 PROPRANOLOL ____________________________________________________________________ 93

02.05 DRUGS AFFECTING THE RENIN-ANGIO-TENSIN SYSTEM AND SOME



Pages:   || 2 | 3 | 4 | 5 |   ...   | 172 |


Similar works:

«Package leaflet: Information for the patient DUAVIVE 0.45 mg/20 mg modified-release tablets Conjugated oestrogens/bazedoxifene Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.Keep this leaflet. You may need to read it again.If you have any further questions, ask your doctor or pharmacist.This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the...»

«ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Plenadren 5 mg modified-release tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each modified-release tablet contains hydrocortisone 5 mg. For a full list of excipients, see section 6.1.3. PHARMACEUTICAL FORM Modified-release tablet. The tablets are round (diameter 8 mm), convex and pink. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of adrenal insufficiency in adults. 4.2 Posology and method of...»

«Package leaflet: Information for the user Sunveniz XL 37.5 mg prolonged-release tablets Sunveniz XL 75 mg prolonged release tablets Sunveniz XL 150 mg prolonged release tablets Venlafaxine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.Keep this leaflet. You may need to read it again.If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to...»

«Scrap Tires in Ciudad Juárez and El Paso: Ranking the Risks Allen Blackman and Alejandra Palma September 2002 • Discussion Paper 02–46 Resources for the Future 1616 P Street, NW Washington, D.C. 20036 Telephone: 202–328–5000 Fax: 202–939–3460 Internet: http://www.rff.org © 2002 Resources for the Future. All rights reserved. No portion of this paper may be reproduced without permission of the authors. Discussion papers are research materials circulated by their authors for purposes...»

«Package leaflet: Information for the user TREVICTA 175 mg prolonged release suspension for injection TREVICTA 263 mg prolonged release suspension for injection TREVICTA 350 mg prolonged release suspension for injection TREVICTA 525 mg prolonged release suspension for injection Paliperidone Read all of this leaflet carefully before you start using this medicine because it contains important information for you.Keep this leaflet. You may need to read it again.If you have any further questions,...»

«PACKAGE LEAFLET: INFORMATION FOR THE USER Valsartan 40 mg Capsules Valsartan 80 mg Capsules Valsartan 160 mg Capsules Valsartan Read all of this leaflet carefully before you start taking this medicine.• Keep this leaflet. You may need to read it again.• If you have any further questions, ask your doctor or pharmacist.• This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets...»

«SELF-REGULATION FROM BIRTH TO AGE SEVEN: ASSOCIATIONS WITH MATERNAL MENTAL HEALTH, PARENTING, AND SOCIAL, EMOTIONAL AND BEHAVIOURAL OUTCOMES FOR CHILDREN Kate Elizabeth Williams RMT BMus PGDipMusThy MEd(Research) Supervisors: Professor Donna Berthelsen Associate Professor Sue Walker Professor Jan M. Nicholson This thesis is submitted for the degree of Doctor of Philosophy (PhD) School of Early Childhood Faculty of Education Queensland University of Technology ABSTRACT This research is focussed...»

«APPENDIX D PBL questions and answers Fluids, Electrolytes and Acid/Base Balance PROBLEM 1 Severe Hypochloremic, Hypokalemic Metabolic Alkalosis with Intravascular Volume Deficit A 45 year old man with previously known duodenal ulcer disease presents with complaints of persistent vomiting for the past 36 hours. The vomit is clear-looking and acidic in taste. He has no abdominal pain. Prior to the vomiting, he had difficulty with solid foods causing fullness in the stomach and he had been taking...»

«Package leaflet: Information for the user Bisoprolol HCT STADA 2.5 mg/6.25 mg, 5 mg/12.5 mg and 10 mg/25 mg film-coated tablets Bisoprolol/ Hydrochlorothiazide Read all of this leaflet carefully before you start taking this medicine becaus it contains important information for you.  Keep this leaflet. You may need to read it again.  If you have any further questions, ask your doctor or pharmacist.  This medicine has been prescribed for you only. Do not pass it on to others. It may harm...»

«This guide is not intended to provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this guide, Sage Products provides general information for educational purposes only. The information provided in this guide is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Sage Products is not liable...»

«Pink Himalayan Salt Top 14 Healing Secrets 1. Fights Diabetes & Normalizes Blood Sugar One of the most vital and crucial benchmark of our body health is our blood sugar level. Having too low or too high a blood sugar has its corresponding disadvantages and if the problem becomes extreme it can be very hard on our body. Chronic high blood sugar can result in developing a disease called diabetes. However, for people who are already diabetic, ample intake of Himalayan salt will put the body into...»

«16 Chronic Periaortitis as a Systemic Autoimmune Disease Chang-Hee Suh Rheumatology, Ajou University School of Medicine Korea 1. Introduction Chronic periaortitis is an idiopathic disease whose hallmark is the presence of a fibroinflammatory tissue arising from the adventitia of the abdominal aorta and the common iliac arteries and extending into the surrounding retroperitoneum and frequently encasing neighboring structures such as the ureters and the inferior vena cava (Mitchinson, 1984;...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.